This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Nov. 16, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that
Mark D. Myslinski has been appointed senior vice president and chief commercial officer of the company.
Mr. Myslinski has nearly 30 years of life sciences and diagnostics industry experience with Fortune 100 and venture-backed startup organizations. He was recently president and CEO of RedPath Integrated Pathology, Inc. where he and the team transformed the company from a research and market development focus to full commercialization of a novel molecular diagnostic assay in a Clinical Laboratory Improvements Amendments (CLIA) certified laboratory.
"Mark's extensive experience in diagnostics and his leadership within the life science community will be invaluable to Saladax as the company targets new markets for the commercialization of its MyCare assays," said
Kevin Harter, president and CEO of Saladax. "In particular, Mark's expertise will be critical as Saladax pursues the formation of a laboratory that meets CLIA standards."
Previous to Mr. Myslinski's time at RedPath Integrated Pathology, Inc., he served as vice president of evidence-based medicine at Ortho Clinical Diagnostics, Inc. and general manager, molecular and cellular diagnostics division of Veridex, LLC, both of which are Johnson & Johnson companies.
"I'm excited to join Saladax during this time of rapid growth with the formation of a CLIA certified laboratory at the company's headquarters and the continued expansion of its MyCare assays worldwide," said Mr. Myslinski. "Saladax's solutions offer patients a means of personalized chemotherapy treatment by finding the optimal dose for each individual patient. This is very important to clinical outcomes by assuring the right dosage gets delivered to the patient in the most efficient manner."